ИСПОЛЬЗОВАНИЕ ПСИХОДЕЛИЧЕСКИХ ВЕЩЕСТВ В ТЕРАПЕВТИЧЕСКИХ ЦЕЛЯХ: ЯТРОГЕНИЯ ИЛИ ОБОСНОВАННАЯ НЕОБХОДИМОСТЬ? ЧАСТЬ 1
- Авторы: Асадуллин А.Р.1, Анцыборов А.В.2
-
Учреждения:
- Башкирский государственный медицинский университет
- Медицинский центр «Альфа Центр Здоровья»
- Выпуск: Том L, № 2 (2018)
- Страницы: 61-71
- Раздел: Статьи
- URL: https://journals.rcsi.science/1027-4898/article/view/14113
- DOI: https://doi.org/10.17816/nb14113
- ID: 14113
Цитировать
Полный текст
Аннотация
Галлюциногенные вещества принято подразделять на несколько различных классов. Большинство имеющихся классификаций основаны на фармакологических механизмах действия данных веществ и их химической структуре. К довольно большой группе веществ с галлюциногенным действием принято относить психоделики, энтактогены, диссоциативные вещества и «атипичные» галлюциногены. Вышеперечисленные классы веществ в основе своей не имеют общих первичных механизмов действия. При этом они схожи в способности вызывать временные, различные по глубине изменения сознания, сочетающиеся с изменениями в соматическом статусе, сфере перцепции, когнитивных процессах и эмоциональной сфере. Подобные изменения способствуют рекреационному употреблению веществ этой группы. В последние годы в научной литературе появилось большое число работ, указывающих на возможность использования данных веществ в терапевтических целях. В настоящем обзоре представлены современные литературные данные по нескольким классам галлюциногенов, терапевтическое применение которых максимально документировано.
Ключевые слова
Полный текст
Открыть статью на сайте журналаОб авторах
Азат Раилевич Асадуллин
Башкирский государственный медицинский университет
Email: droar@yandex.ru
г. Уфа, ул. Ленина, д. 3
Андрей Викторович Анцыборов
Медицинский центр «Альфа Центр Здоровья»
Email: andrei.v.ancyborov@gmail.com
г. Ростов-на-Дону, ул. Социалистическая, д. 154а
Список литературы
- Abramson H.A., Rolo A. Comparison of LSD with methysergide and psilocybin on test subjects / The Use of LSD in Psychotherapy and Alcoholism, ed. Abramson, HA. 1967. С. 53-73
- Aghajanian G.K., Marek G.J. Serotonin and hallucino-gens // Neuropsychopharmacology. 1999. Vol. 21 (Suppl, 2). P. 16S-23S
- Albaugh B.J., Anderson P.O. Peyote in the treatment of alcoholism among American Indians // American journal of Psychiatry. 1974. Vol. 131, № 11. P. 1247-1250
- Asadullin A.R. et al. Approach to Classifying “Design” Drugs and New Potentially Dangerous Chemical Substances, with a Brief Review of the Problem // International Journal of Environmental and Science Education. 2016. Vol. 11, № 14. С. 6697-6703
- Auerbach R., Rugowski J.A. Lysergic acid diethylamide: effect on embryos // Science. 1967. Vol. 157, № 3794. P. 1325-1326
- Baggott M. J. et al. Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire // Drug & Alcohol Dependence. 2011. Vol. 114, № 1. P. 61-67
- Bergman R. L. Navajo peyote use: Its apparent safety // American Journal of Psychiatry. 1971. Vol. 128, №. 6. P. 695-699
- Bergquist L. The curious story behind the new Cary Grant // Look, September. 1959. Vol. 1
- Bogenschutz M.P. et al. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study // Journal of psychopharmacology. 2015. Vol. 29, № 3. P. 289-299
- Brodie B. B., Shore P. A. A concept for a role of serotonin and norepinephrine as chemical mediators in the brain // Annals of the New York Academy of Sciences. 1957. Vol. 66, № 1. P. 631-642
- Bruhn J.G. et al. Mescaline use for 5700 years // The Lancet. 2002. Vol. 359, № 9320. P. 1866
- Carbonaro T.M. et al. The role of 5-HT 2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N, N-dimethyltryptamine and N, N-diisopropyltryptamine in rats and mice // Psychopharmacology. 2014. Vol. 232, № 1. P. 275-284
- Carhart-Harris R.L. et al. LSD enhances suggestibility in healthy volunteers // Psychopharmacology. 2014_a. Vol. 232, №. 4. P. 785-794
- Carhart-Harris R.L. et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin // Proceedings of the National Academy of Sciences. 2012. Vol. 109, №. 6. P. 2138-2143
- Carhart-Harris R.L. et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study // The Lancet Psychiatry. 2016. Vol. 3, № 7. P. 619-627
- Carhart-Harris R.L., Nutt D.J. Experienced drug users assess the relative harms and benefits of drugs: a web-based survey // Journal of psychoactive drugs. 2013. Vol. 45, № 4. P. 322-328
- Caudevilla-Gálligo F. et al. 4-Bromo-2, 5-dimethoxy-phenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects // Journal of Psychopharmacology. 2012. Vol. 26, № 7. P. 1026-1035
- Chwelos N. et al. Use of d-lysergic acid diethylamide in the treatment of alcoholism // Quarterly journal of studies on alcohol. 1959. Vol. 20. P. 577-590
- Cohen M.M., Marinello M.J., Back N. Chromosomal damage in human leukocytes induced by lysergic acid diethylamide // Science. 1967. Vol. 155, № 3768. P. 1417-1419
- Cohen M.M., Shiloh Y. Genetic toxicology of lysergic acid diethylamide (LSD-25) // Mutation Research/Reviews in Genetic Toxicology. 1977. Vol. 47, № 3-4. P. 183-209
- Cohen S. Lysergic Acid Diethylamide //The Journal of nervous and mental disease. 1960. Vol. 130, №. 1. P. 30-40
- Cohen S. The therapeutic potential of LSD-25 / A Pharmacologic Approach to the Study of the Mind [eds. RM Featherstone and A. Simon]. Springfield, Ill.: Thomas, 1959
- Cozzi N. V. Psychedelic breakthroughs in neuroscience: How psychedelic drugs influenced the growth and development of psychopharmacology // MAPS Bulletin. 2013. Vol. 23, № 1. P. 16-19
- de Verges G. Constitutional Law: Freedom of Religion: Peyote and the Native American Church // American Indian Law Review. 1974. Т. 2, № 2. С. 71-79
- Deniker P. Biological changes in man following intravenous administration of mescaline // The Journal of nervous and mental disease. 1957. Т. 125, № 3. С. 427-431
- Dishotsky N.I. et al. LSD and genetic damage // Science. 1971. Vol. 172, № 3982. P. 431-440
- Doblin R. Pahnke’s “Good Friday Experiment”: A long-term follow-up and methodological critique // The Journal of Transpersonal Psychology. 1991. Vol. 23, № 1. P. 1
- Drevets W.C., Price J.L., Furey M.L. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression // Brain structure and function. 2008. Vol. 213, № 1-2. P. 93-118
- Duncan D.F., Gold R.S. Drugs and the whole person. Macmillan Publishing Company, 1982
- Dyck E. Flashback: psychiatric experimentation with LSD in historical perspective // The Canadian Journal of Psychiatry. 2005. Vol. 50, №. 7. P. 381-388
- Egozcue J., Irwin S., Maruffo C. A. Chromosomal damage in LSD users // Jama. 1968. Vol. 204, № 3. P. 214-218
- Eisner B.G., Cohen S. Psychotherapy with lysergic acid diethylamide, 1958
- El-Seedi H.R. et al. Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas // Journal of ethnopharmacology. 2005. Vol. 101, №. 1-3. P. 238-242
- Evarts E.V. A review of the neurophysiological effects of lysergic acid diethylamide (LSD) and other psychotomimetic agents // Annals of the New York Academy of Sciences. 1957. Vol. 66, № 1. P. 479-495
- Fadiman J. The psychedelic explorer’s guide: Safe, therapeutic, and sacred journeys. Simon and Schuster, 2011
- Faillace L.A., Snyder S.H., Weingartner H. 2, 5-dimethoxy-4-methylamphetamine: clinical evaluation of a new hallucinogenic drug // Journal of Nervous and Mental Disease. 1970
- Fantegrossi W.E., Murnane K.S., Reissig C.J. The behavioral pharmacology of hallucinogens // Biochemical pharmacology. 2008. Vol. 75, № 1. P. 17-33
- Fantegrossi W. E., Woods J. H., Winger G. Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys // Behavioural pharmacology. 2004. Vol. 15, № 2. P. 149-157
- Garcia-Romeu A., Griffiths R., Johnson M. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction // Current drug abuse reviews. 2014. Vol. 7, № 3. P. 157-164
- Garrity J.F. Jesus, peyote, and the holy people: alcohol abuse and the ethos of power in Navajo healing // Medical Anthropology Quarterly. 2000. Vol. 14, №4. P. 521-542
- Gasser P. et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases // The Journal of nervous and mental disease. 2014. Vol. 202, № 7. P. 513
- Gasser P., Kirchner K., Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects // Journal of Psychopharmacology. 2014_b. Vol. 29, № 1. P. 57-68
- Geyer M.A. Lysergic acid diethylamide and psilocybin revisited // Biological psychiatry. 2015. Vol. 78, № 8. P. 516-518
- Glass G.S., Bowers M.B. Chronic psychosis associated with long-term psychotomimetic drug abuse // Archives of general psychiatry. 1970. Vol. 23, № 2. P. 97-103
- Glennon R.A., Young R., Rosecrans J.A. Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists // European journal of pharmacology. 1983. Vol. 91, № 2-3. P. 189-196
- Greiner T., Burch N. R., Edelberg R. Psychopathology and psychophysiology of minimal LSD-25 dosage: A preliminary dosage-response spectrum // AMA Archives of Neurology & Psychiatry. 1958. Vol. 79, № 2. P. 208-210
- Griffiths R.R. et al. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later // Journal of psychopharmacology. 2008. Vol. 22, № 6. P. 621-632
- Griffiths R.R. et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance // Psychopharmacology. 2006. Vol. 187, № 3. P. 268-283
- Griffiths R.R. et al. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects // Psychopharmacology. 2011. Vol. 218, № 4. P. 649-665
- Grinspoon L., Bakalar J. B. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research // Journal of psychoactive drugs. 1997. Vol. 30, № 2. P. 171-177
- Grob C.S. et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer // Archives of general psychiatry. 2011. Vol. 68, № 1. P. 71-78
- Grof S. et al. LSD-assisted psychotherapy in patients with terminal cancer // International pharmacopsychiatry. 1972. Vol. 8. P. 129-144
- Guerra-Doce E. Psychoactive substances in prehistoric times: examining the archaeological evidence // Time and Mind. 2015. Vol. 8, № 1. P. 91-112
- Halberstadt A. L. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens // Behavioural brain research. 2014. Vol. 277. P. 99-120
- Halpern J.H. et al. Psychological and cognitive effects of long-term peyote use among Native Americans // Biological psychiatry. 2005. Vol. 58, № 8. P. 624-631
- Halpern J.H., Pope H.G. Hallucinogen persisting perception disorder: what do we know after 50 years? // Drug & Alcohol Dependence. 2003. Vol. 69, № 2. P. 109-119
- Harman W.W. et al. Psychedelic agents in creative problem-solving: A pilot study // Psychological reports. 1966. Vol. 19, № 1. P. 211-227
- Heffter A. Ueber Cacteenalkaloi // der. Ber Dtsch Chem Ges. 1896. Vol. 29, № 216. P. 27
- Hermle L. et al. Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research // Biological psychiatry. 1992. Vol. 32, № 11. P. 976-991
- Hermle L., Gouzoulis-Mayfrank E., Spitzer M. Blood flow and cerebral laterality in the mescaline model of psychosis // Pharmacopsychiatry. 1998. Vol. 31, № S 2. P. 85-91
- Hoffmeister F., Wuttke W. Psychotropic drugs as negative reinforces // Pharmacological reviews. 1975. Vol. 27, № 3. P. 419-428
- Hofmann A. et al. Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen Rausch pilz Psilocybe mexicana Heim // Experientia. 1958. Vol. 14, № 3. P. 107-109
- Hofmann A. How LSD originated // Journal of psychedelic drugs. 1979. Vol. 11, № 1-2. P. 53-60
- Hofmann A. LSD: my problem child. Oxford University Press, 2013
- Hollister L.E., Hartman A.M. Mescaline, lysergic acid diethylamide and psilocybin: comparison of clinical syndromes, effects on color perception and biochemical measures // Comprehensive Psychiatry. 1962. Vol. 3, № 4. P. 235-241
- Isbell H. Comparison of the reactions induced by psilocybin and LSD-25 in man // Psychopharmacology. 1959. Vol. 1, № 1. P. 29-38
- Isbell H. et al. Studies on lysergic acid diethylamide (LSD-25): 1. Effects in former morphine addicts and development of tolerance during chronic intoxication // AMA Archives of Neurology & Psychiatry. 1956. Vol. 76, № 5. P. 468-478
- Isbell H. et al. Studies on lysergic acid diethylamide (LSD-25): 1. Effects in former morphine addicts and development of tolerance during chronic intoxication // AMA Archives of Neurology & Psychiatry. 1956. Vol. 76, № 5. P. 468-478
- Johnson M.W. et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction // Journal of psychopharmacology. 2014. Vol. 28, № 11. P. 983-992
- Johnson M.W., Richards W. A., Griffiths R.R. Human hallucinogen research: guidelines for safety // Journal of psychopharmacology. 2008. Vol. 22, № 6. P. 603-620
- Johnson M.W., Sewell R.A., Griffiths R.R. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers // Drug & Alcohol Dependence. 2012. Vol. 123, № 1. P. 132-140
- Kaelen M. et al. LSD enhances the emotional response to music // Psychopharmacology. 2015. Vol. 232, № 19. P. 3607-3614
- Kast E.C., Collins V.J. Study of lysergic acid diethylamide as an analgesic agent // Anesthesia & Analgesia. 1964. Vol. 43, № 3. P. 285-291
- Katz S. My 12 hours as a madman // Maclean’s. 1953. Vol. 108, № 52. P. 69-70
- Keeler M.H., Ewing J.A., Rouse B.A. Hallucinogenic effects of marijuana as currently used // American Journal of Psychiatry. 1971. Vol. 128, № 2. P. 213-216
- Kirsch I., Low C.B. Suggestion in the treatment of depression // American Journal of Clinical Hypnosis. 2013. Vol. 55, № 3. P. 221-229
- Kraehenmann R. et al. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers // Biological psychiatry. 2014. Vol. 78, № 8. P. 572-581
- Krebs T.S., Johansen P.Ø. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials // Journal of Psychopharmacology. 2012. Vol. 26, № 7. P. 994-1002
- Leary T., Litwin G.H., Metzner R. Reactions to psilocybin administered in a supportive environment // Journal of Nervous and Mental Disease. 1963
- Lee M.A., Shlain B. Acid dreams: The complete social history of LSD: The CIA, the sixties, and beyond. Grove Press, 1992
- Lewin L. Phantastica: narcotic and stimulating drugs, their use and abuse, 1931
- Li H.L. An archaeological and historical account of cannabis in China // Economic Botany. 1973. Vol. 28, № 4. P. 437-448
- MacLean K.A., Johnson M.W., Griffiths R.R. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness // Journal of Psychopharmacology. 2011. Vol. 25, № 11. P. 1453-1461
- Malitz S. et al. Some observations on psilocybin, a new hallucinogen, in volunteer subjects // Comprehensive psychiatry. 1960
- Mangini M. Treatment of alcoholism using psychedelic drugs: a review of the program of research // Journal of psychoactive drugs. 1998. Vol. 30, № 4. p. 381-418
- Mashour G.A. From LSD to the IRB: Henry Beecher’s psychedelic research and the foundation of clinical ethics // International anesthesiology clinics. 2007. Vol. 45, № 4. P. 105-111
- Masters R., Houston J. The varieties of psychedelic experience: The classic guide to the effects of LSD on the human psyche. Simon and Schuster, 2000
- McGlothlin W.H., Arnold D.O. LSD revisited: A ten-year follow-up of medical LSD use // Archives of General Psychiatry. 1971. Vol. 24, №. 1. P. 35-49
- McGlothlin W., Cohen S., McGlothlin M.S. Long lasting effects of LSD on normal // Archives of General Psychiatry. 1967. Vol. 17, № 5. P. 521-532
- McKenna D., Riba J. New World tryptamine hallucinogens and the neuroscience of ayahuasca. 2015
- McKinney C.H. et al. Effects of guided imagery and music (GIM) therapy on mood and cortisol in healthy adults // Health psychology. 1997. Vol. 16, № 4. P. 390
- Metzner R. Teonanacatl: sacred mushroom of visions // Four Tree, El Verano, CA. 2004. Vol. 25
- Moreno F. A. et al. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder // Journal of Clinical Psychiatry. 2006. Vol. 67, № 11. P. 1735-1740
- Moreno J.L. et al. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists // Neuroscience letters. 2011. Vol. 493, № 3. P. 76-79
- Morris H., Wallach J. From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs // Drug testing and analysis. 2014. Т. 6, № 7-8. P. 614-632
- Nichols D.E. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens // Journal of psychoactive drugs. 1986. Vol. 18, № 4. P. 305-313
- Nichols D. E. Hallucinogens // Pharmacology & therapeutics. 2004. Vol. 101, № 2. P. 131-181
- Nichols D. E. Psychedelics // Pharmacological reviews. 2016. Vol. 68, № 2. P. 264-355
- Nutt D.J. et al. Drug harms in the UK: a multicriteria decision analysis // The Lancet. 2010. Vol. 376, № 9752. P. 1558-1565
- Nutt D. J., King L. A., Nichols D. E. Effects of Schedule I drug laws on neuroscience research and treatment innovation // Nature Reviews Neuroscience. 2013. Vol. 14, № 8. P. 577
- Nutt D. Mind-altering drugs and research: from presumptive prejudice to a Neuroscientific Enlightenment?: Science & Society series on “Drugs and Science” // EMBO reports. 2014. Vol. 15, № 3. P. 208-211
- Osmond H. A review of the clinical effects of psychotomimetic agents // Annals of the New York Academy of Sciences. 1957. Vol. 66, № 1. P. 418-434
- Ott J. Pharmacotheon // Natural Products Co., Kennewick, USA. 1993
- Pahnke W.N. Psychedelic drugs and mystical experience // International psychiatry clinics. 1969. Vol. 5, № 4. P. 149
- Pahnke W.N. Psychedelic drugs and mystical experience // International psychiatry clinics. 1963. Vol. 5, № 4. P. 149
- Pahnke W.N., Richards W.A. Implications of LSD and experimental mysticism // Journal of Religion and Health. 1966. Vol. 5, № 3. P. 175-208
- Passie T. et al. The pharmacology of lysergic acid diethylamide: a review // CNS Neuroscience & Therapeutics. 2008. Vol. 14, № 4. P. 295-314
- Passie T. et al. The pharmacology of psilocybin // Addiction biology. 2002. Vol. 7, № 4. P. 357-364
- Patterson D.R., Jensen M.P. Hypnosis and clinical pain // Psychological bulletin. 2003. Vol. 129, № 4. P. 495
- Pieri L., Pieri M., Haefely W. LSD as an agonist of dopamine receptors in the striatum // Nature. 1974. Vol. 252, № 5484. P. 586
- Poling A., Bryceland J. Voluntary Drug Self-Administration by Nonhumans; A Review // Journal of psychedelic drugs. 1979. Vol. 11, № 3. P. 185-190
- Presti D. E., Nichols D. E. Biochemistry and neuropharmacology of psilocybin mushrooms / Teonanacatl. Four Trees, El Verano, CA, 2004. P. 89-108
- Prue B. Indigenous supports for recovery from alcoholism and drug abuse: The Native American Church // Journal of Ethnic And Cultural Diversity in Social Work. 2013. Vol. 22, № 3-4. P. 271-287
- Ray T.S. Psychedelics and the human receptorome // PLoS One. 2010. Vol. 5, № 2. P. e9019
- Rinkel M. Pharmacodynamics of LSD and mescaline // The Journal of nervous and mental disease. 1957. Vol. 125, № 3. P. 424-426
- Ruck C.A., Bigwood J., Staples D. et al. Entheogens // Journal of Psychoactive Drugs. 1979. Vol. 11, № 1-2. P. 145-146
- Sandison R.A., Spencer A.M., Whitelaw J.D.A. The therapeutic value of lysergic acid diethylamide in mental illness // The British Journal of Psychiatry. 1954. Vol. 100, № 419. P. 491-507
- Savage C., McCabe O. L. Residential psychedelic (LSD) therapy for the narcotic addict: a controlled study // Archives of General Psychiatry. 1973. Vol. 28, № 6. P. 808-814
- Schindler E.A.D. et al. Indoleamine hallucinogens in cluster headache: results of the Clusterbusters medication use survey // Journal of psychoactive drugs. 2015. Vol. 47, № 5. P. 372-381
- Schmid Y. et al. Acute effects of lysergic acid diethylamide in healthy subjects // Biological psychiatry. 2015. Vol. 78, № 8. p. 544-553
- Schultes R.E. Teonanácatl: The narcotic mushroom of the Aztecs // American Anthropologist. 1940. Vol. 42, № 3. P. 429-443
- Schultes R.E., Hofmann A. Plants of the gods: their sacred, healing, and hallucinogenic powers. 2001
- Schuster C.R., Thompson T. Self administration of and behavioral dependence on drugs // Annual review of pharmacology. 1969. Vol. 9, № 1. P. 483-502
- Sewell R.A., Halpern J.H., Pope H.G. Response of cluster headache to psilocybin and LSD // Neurology. 2006. Vol. 66, № 12. P. 1920-1922
- Shulgin A. T. Mescaline: The chemistry and pharmacology of its analogs // Lloydia. 1973, Vol. 36, № 1-4. P. 46-58
- Shulgin A.T., Nichols D.E. The Pharmacology of hallucinogens. Characteristics of three new psychotomimetics.(1stedn.). 1978
- Shulgin A., Shulgin A. PIHKAL: Phenethylamines I have known and loved. Transform Press, 1995
- Smart R.G. et al. A controlled study of lysergide in the treatment of alcoholism: I. The effects on drinking behavior // Quarterly journal of studies on alcohol. 1967
- Smart R.G., Storm T. The Efficacy of LSD in the Treatment of Alcoholism // QJ Stud Alcohol. 1964. Vol. 25. P. 333-338
- Stamets P. Psilocybin mushrooms of the world. Ten Speed Press, 1996
- Stoll W.A. Lysergic Acid Diethylamide, a Phantastikum from the ergot Group // Schweizer Archiv fur Neurologie und Psychiatrie. 1947. Vol. 60, № 1-2. P. 279-323
- Strassman R.J. Adverse reactions to psychedelic drugs. A review of the literature // J Nerv Ment Dis. 1984. Vol. 172, № 10. P. 577-595
- Strassman R.J. Perspectives and Prospects // The Journal of nervous and mental disease. 1995_a. Vol. 183, № 3. P. 127-138
- Studerus E. et al. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies // Journal of Psychopharmacology. 2011. Vol. 25, № 11. P. 1434-1452
- Studerus E. et al. Prediction of psilocybin response in healthy volunteers // PLoS One. 2012. Vol. 7, № 2. P. e30800
- Terracciano A. et al. Hierarchical linear modeling analyses of the NEO-PI-R scales in the Baltimore Longitudinal Study of Aging // Psychology and aging. 2005. Vol. 20, № 3. P. 493
- Titeler M. Radioligand binding evidence implivates the brain 5-HT2 receptor as a site-of action for LSD and phenylisopropylamine hallucinogens // Biochem Pharmacol. 1988. Vol. 36. P. 3265-3271
- Tupper K. W. et al. Psychedelic medicine: a re-emerging therapeutic paradigm // Canadian Medical Association Journal. 2015. Vol. 187, № 14. P. 1054-1059
- Van Amsterdam J. et al. Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population // European Addiction Research. 2010. Vol. 16, № 4. P. 202-207
- Van Amsterdam J., Opperhuizen A., van den Brink W. Harm potential of magic mushroom use: a review // Regulatory toxicology and pharmacology.2011. Vol. 59, № 3. P. 423-429
- Vollenweider F.X. et al. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man-a PET study with [11 C] raclopride // Neuropsychopharmacology. 1999. Vol. 20, № 5. P. 424
- Vollenweider F.X. et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action // Neuroreport. 1998. Vol. 9, № 17. P. 3897-3902
- Vollenweider F.X., Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders // Nature Reviews Neuroscience. 2010. Vol. 11, № 9. P. 642
- Wasson R.G. The wondrous mushroom: mycolatry in Mesoamerica. McGraw-Hill, 1980. № 7
- Whitaker-Azmitia P.M. The discovery of serotonin and its role in neuroscience // Neuropsychopharmacology. 1999. Vol. 21, № S1. P. 2S
- Wolbach A.B., Miner E.J., Isbell H. Comparison of psilocin with psilocybin, mescaline and LSD-25 // Psychopharmacology. 1962. Vol. 3, № 3. P. 219-223
- Woolley D.W., Shaw E. A biochemical and pharmacological suggestion about certain mental disorders // Proceedings of the National Academy of Sciences. 1954_a. Vol. 40, № 4. P. 228-231
- Woolley D.W., Shaw E. Some neurophysiological aspects of serotonin // British medical journal. 1954_b. Vol. 2, № 4880. P. 122
- Woolley D.W., Shaw F.N. Evidence for the participation of serotonin in mental processes // Annals of the New York Academy of Sciences. 1957. Vol. 66, № 1. P. 649-667